**Understated Earnings Create Opportunity in These Stocks**

Reported earnings numbers may drive short-term stock price movements, but in the long-term, markets allocate capital to the firms that generate the greatest return per dollar invested into the business. Analysts and investors have historically focused on reported earnings due to the difficulty of measuring return on invested capital (ROIC) accurately at scale.

Accurately measuring the return a business generates requires numerous accounting adjustments and analysis of the footnotes and MD&A of 10-K filings. By performing this diligence, one can calculate a business' true economic earnings, invested capital, after-tax profit (NOPAT), and ROIC. Through this research, we found five stocks with rising economic earnings that the market might have overlooked due to declining GAAP earnings.

This week we highlight three of these stocks as Long Ideas: Amgen Inc. (AMGN: $183/share), Colgate-Palmolive Company (CL: $71/share), and Hanesbrands Inc. (HBI: $19/share).

**Diligence Reveals Undervalued Stocks**

During filing season, we leverage our Robo-Analyst technology to parse and analyze ~2,000 10-Ks. Since mid-February, we have made 38,887 adjustments to reported income statements and balance sheets with a dollar value of $13.7 trillion.

Through this work, we are able to identify firms whose 2017 reported GAAP net income understates the true profitability of the firm. In the S&P 500, 46 stocks with either a 12/31 or 1/31 fiscal year end reported falling GAAP net income but grew economic earnings in 2017. Of this group, 15 receive an Attractive or better rating, which not only takes into account quality of earnings, but also a stock’s valuation. We then analyzed these 15 stocks to determine which were undervalued relative to the overall market.

**Figure 1: Identifying the Cheapest Stocks in the S&P 500 Based on ROIC**

![Graph showing stocks with rising economic earnings and below-average valuations](image)

Sources: New Constructs, LLC and company filings

---

1. Ernst & Young’s recent white paper, “Getting ROIC Right”, proves the superiority of our research and analytics.
Per Figure 1, Amgen, Colgate-Palmolive Company and Hanesbrands are all trading below their fair valuation based on relative ROIC.

**Accounting Adjustments Reveal Profitability Greater Than Reported**

Investors looking for value in the current volatile market should start with the stocks highlighted above. Per Figure 2, each of these stocks grew economic earnings in 2017 despite reported GAAP net income declining.

**Figure 2: Change in GAAP Net Income vs. Change in Economic Earnings in 2017**

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Net Income % Change</th>
<th>Economic Earnings % Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>-74%</td>
<td>4%</td>
</tr>
<tr>
<td>CL</td>
<td>-17%</td>
<td>1%</td>
</tr>
<tr>
<td>HBI</td>
<td>-89%</td>
<td>1%</td>
</tr>
</tbody>
</table>

Sources: New Constructs, LLC and company filings

The disconnect in net income and economic earnings is caused by accounting rules that fail to adequately measure the true cash flows of a business. Items such as **asset write-downs**, **non-operating expense**, **off-balance sheet debt**, **over/under-funded pensions**, and **excess cash** must be accounted for when analyzing income statements and balance sheets. Figure 3 highlights the adjustments made to AMGN, CL and HBI’s 2017 10-K to calculate economic earnings.

**Figure 3: Economic Earnings Greater than Reported GAAP Net Income**

<table>
<thead>
<tr>
<th>Adjustments for Economic Earnings</th>
<th>AMGN</th>
<th>CL</th>
<th>HBI</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAAP Net Income</td>
<td>$1,979</td>
<td>$2,024</td>
<td>$62</td>
</tr>
<tr>
<td>Hidden Non-Operating Items</td>
<td>$524</td>
<td>$258</td>
<td>$213</td>
</tr>
<tr>
<td>Reported Non-Operating Items</td>
<td>$376</td>
<td>$296</td>
<td>$214</td>
</tr>
<tr>
<td>Change in Reserves</td>
<td>$0</td>
<td>$33</td>
<td>$0</td>
</tr>
<tr>
<td>Implied Interest for Off-Balance Sheet Debt</td>
<td>$28</td>
<td>$33</td>
<td>$27</td>
</tr>
<tr>
<td>Non-Operating Tax Adjustment</td>
<td>$6,005</td>
<td>$7</td>
<td>$423</td>
</tr>
<tr>
<td>After-Tax Non-Operating Expense</td>
<td>$0</td>
<td>$150</td>
<td>$2</td>
</tr>
<tr>
<td>NOPAT</td>
<td><strong>$8,913</strong></td>
<td><strong>$2,801</strong></td>
<td><strong>$940</strong></td>
</tr>
<tr>
<td>Capital Charge for Invested Capital</td>
<td>-$2,601</td>
<td>-$710</td>
<td>-$344</td>
</tr>
<tr>
<td>Economic Earnings</td>
<td><strong>$6,311</strong></td>
<td><strong>$2,091</strong></td>
<td><strong>$596</strong></td>
</tr>
</tbody>
</table>

Sources: New Constructs, LLC and company filings

**Amgen Inc. (AMGN: $183/share)**

Amgen, a biotech that closely resembles a traditional pharma firm, reported a 74% decline in GAAP net income in 2017 but economic earnings grew 4%. Much of this decline can be attributed to a $6.1 billion charge related to 2017 Tax Act, but there remain expenses hidden in operating earnings that cause significant understatement of AMGN’s reported profitability.

On page 51, AMGN disclosed $88 million in restructuring costs and $146 million in pre-tax expenses related to Hurricane Maria. Then, on page F-13 (page 89 overall), the firm disclosed an impairment charge of $400 million related to the discontinuation of development of AMG 899. These one-time costs are hidden within operating expenses and artificially reduce reported GAAP net income.

On the balance sheet, we add $559 million in **off-balance sheet operating leases** and another $679 million in **accumulated other comprehensive income** to our calculation of invested capital. Doing so allows us to hold a business accountable for all capital invested in the business and calculate an accurate ROIC.
As with all the companies in Figure 3, Amgen’s true profitability is not only greater than its reported earnings, but the stock is currently undervalued. Since we first featured AMGN as a Long Idea in May 2017, the stock is up 12% while the S&P 500 is up 13%. If AMGN was valued in line with the rest of the market, or at the level implied by the trend line in Figure 1, the stock would be worth $310/share today – a 70% upside.

At its current price of $183/share, the stock has a price-to-economic book value (PEBV) ratio of 1.0. This ratio means the market expects AMGN’s NOPAT to never meaningfully grow from current levels. This expectation would seem rather pessimistic given that the firm has grown NOPAT by 11% compounded annually since 2012.

**Colgate-Palmolive Company (CL: $71/share)**

We first featured Colgate-Palmolive in November 2010. Since then, the stock is up 73% while the S&P 500 is up 122%. This manufacturer of numerous consumer products (toothpaste, soaps, deodorants, detergents, shampoos, etc.) reported a 17% decline in GAAP net income in 2017 but economic earnings grew 1%.

On page 79, CL reported an additional $75 million and $89 million in cost of sales and selling, general, and administrative costs, respectively. These non-recurring costs were related to restructuring implementations and are hidden in operating income. Additionally, on page 97, CL reports $94 million in non-operating net periodic benefit costs related to its pension plans.

On the balance sheet, we add $642 million in off-balance sheet operating leases, $3.9 billion in accumulated OCI, and $993 million in assets write-downs to invested capital. These three adjustments are quite significant and, when combined, equal 59% of reported net assets.

After all adjustments, we see that CL’s profitability is not recognized by its current valuation. At its current price of $71/share, CL has a PEBV ratio 1.3. This ratio means the market expects CL’s NOPAT to grow by 30% over the remaining life of the firm. Meanwhile, CL has grown NOPAT by 6% compounded annually since 1998. If the firm can maintain 2017 pre-tax margins (27%), reap the expected benefit of lowered corporate tax rates, and grow NOPAT by 6% compounded annually for the next decade, the stock is worth $93/share today – a 31% upside.

**Hanesbrands Inc. (HBI: $19/share)**

Hanesbrands, a manufacturer of bras, underwear, socks, and more for men, women, and children, reported an 89% decline in GAAP net income in 2017 but economic earnings grew 1%. Similar to AMGN, HBI reported a $457 million charge related to the U.S. tax reform, but that was not the only item hidden in its 10-K. In total, we found $213 million (344% of GAAP net income) in non-operating expenses hidden in operating earnings.

On page F-39 (page 91 overall), HBI reported $18 million in non-operating net periodic benefit costs related to its pension plans. On page F-49 (page 101 overall), HBI revealed that $55 million and $109 million in one-time acquisition and integration costs were included in the cost of sales and selling, general, and administrative line items on the income statement. Also, on this page, HBI reported it incurred over $23 million in employee termination charges.

To calculate invested capital, we removed $235 million in deferred tax assets and $98 million in excess cash. We added back $527 million in off-balance sheet operating leases, $439 million in accumulated OCI, and $173 million in accumulated asset write-downs. Write-downs allow management to erase equity from the balance sheet, which then inflates any return on asset/capital metric. We add back asset write-downs to hold companies accountable for all the capital invested in their business.

Despite the improvement in economic earnings in 2017, the current expectations baked into HBI imply a significant cut in profits. At its current price of $19/share, HBI has a PEBV ratio of 0.6. This ratio means the market expects HBI’s NOPAT to permanently decline by 40%. Such a decline may seem reasonable if one just glanced at the large drop in net income in 2017. However, NOPAT has grown 12% compounded annually over the past decade.

If HBI can maintain current NOPAT margins (15%) and grow NOPAT by just 2% compounded annually for the next decade, the stock is worth $39/share today – a 105% upside.

*This article originally published on March 21, 2018.*

**Disclosure: David Trainer, Sam McBride, and Kyle Guske II receive no compensation to write about any specific stock, style, or theme.**

Follow us on [Twitter](#), [Facebook](#), [LinkedIn](#), and [StockTwits](#) for real-time alerts on all our research.
New Constructs® - Research to Fulfill the Fiduciary Duty of Care

Ratings & screeners on 3000 stocks, 450 ETFs and 7000 mutual funds help you make prudent investment decisions.

New Constructs leverages the latest in machine learning to analyze structured and unstructured financial data with unrivaled speed and accuracy. The firm’s forensic accounting experts work alongside engineers to develop proprietary NLP libraries and financial models. Our investment ratings are based on the best fundamental data in the business for stocks, ETFs and mutual funds. Clients include many of the top hedge funds, mutual funds and wealth management firms. David Trainer, the firm’s CEO, is regularly featured in the media as a thought leader on the fiduciary duty of care, earnings quality, valuation and investment strategy.

To fulfill the Duty of Care, research should be:

1. **Comprehensive** - All relevant publicly-available (e.g. 10-Ks and 10-Qs) information has been diligently reviewed, including footnotes and the management discussion & analysis (MD&A).
2. **Un-conflicted** - Clients deserve unbiased research.
3. **Transparent** - Advisors should be able to show how the analysis was performed and the data behind it.
4. **Relevant** - Empirical evidence must provide [tangible, quantifiable correlation](#) to stock, ETF or mutual fund performance.

**Value Investing 2.0: Diligence Matters: Technology is Key to Value Investing With Scale**

Accounting data is only the beginning of fundamental research. It must be translated into economic earnings to truly understand profitability and valuation. This translation requires deep analysis of footnotes and the MD&A, a process that our [robo-analyst technology](#) empowers us to perform for thousands of stocks, ETFs and mutual funds.
DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, “New Constructs”) is an independent organization with no management ties to the companies it covers. None of the members of New Constructs’ management team or the management team of any New Constructs’ affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs’ Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs’ reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. Copyright New Constructs, LLC 2003 through the present date. All rights reserved.